Selected article for: "activity decrease and liver disease"

Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
  • Document date: 2016_11_8
  • ID: 4fwp1dnl_1
    Snippet: Obesity is a worldwide epidemic that leads to the development of chronic metabolic disorders, such as type 2 diabetes (T2D), cardiovascular disease, and non-alcoholic fatty liver disease (NALFD) (1) (2) (3) . NAFLD is a condition where fat, mainly triglycerides (TG), accumulates in the hepatocytes of patients who have not consumed excessive amounts of alcohol (4) . Estimates of the prevalence of NAFLD range from 6.3% to 33%, depending on the popu.....
    Document: Obesity is a worldwide epidemic that leads to the development of chronic metabolic disorders, such as type 2 diabetes (T2D), cardiovascular disease, and non-alcoholic fatty liver disease (NALFD) (1) (2) (3) . NAFLD is a condition where fat, mainly triglycerides (TG), accumulates in the hepatocytes of patients who have not consumed excessive amounts of alcohol (4) . Estimates of the prevalence of NAFLD range from 6.3% to 33%, depending on the population (5, 6) , and are expected to rise as obesity rates increase, populations become older, and physical activity levels decrease (4) . Moreover, there is an increased prevalence of NAFLD in T2D patients (7) , and its severity may be aggravated by T2D (8, 9) . However, beyond epidemiology, there are many challenges in the diagnosis and treatment of NAFLD.

    Search related documents:
    Co phrase search for related documents